Histone Deacetylases Inhibitor Trichostatin A Increases the Expression of Dleu2/miR-15a/16-1 Via HDAC3 in Non-small Cell Lung Cancer

Overview

Journal Mol Cell Biochem

Publisher Springer

Specialty Biochemistry

Date 2013 Jul 23

PMID 23867991

Citations 34

Authors

Chi-Qi Chen

Cheng-Shui Chen

Jun-Jie Chen

Lian-Ping Zhou

Hong-Lei Xu

Wei-Wei Jin

Jian-Bo Wu

Shen-Meng Gao

Affiliations

Soon will be listed here.

Abstract

Histone deacetylases (HDACs) inhibitor is a promising new approach to the treatment of lung cancer therapy via inhibiting cell growth and inducing apoptosis. miR-15a and miR-16-1 are important tumor suppressors through modulating B cell lymphoma 2 (Bcl-2), Cyclin D1, D2, and others. However, whether HDACs inhibitor modulates the expression of miR-15a/16-1 in lung cancer is still unknown. The purpose of our study was to identify a new miRNA-mediated mechanism which plays an important role in the anti-cancer effects of HDACs inhibitor. We found HDACs inhibitors trichostatin A (TSA) and sodium butyrate upregulated the expression of miR-15a/16-1, residing in the host tumor suppressor Dleu2 gene, through increasing the histone acetylation in the region of Dleu2/miR-15a/16-1 promoter in lung cancer cells. Moreover, among class Ι HDACs subtypes, only knockdown of HDAC3 by specific siRNA increased the hyperacetylation of Dleu2/miR-15a/16-1 promoter region and finally resulted in the upregulation of miR-15a/16-1. Furthermore, overexpression of miR-15a/16-1, which were always deleted or downregulated in lung cancer cells, effectively suppressed cell growth and reduced colony formation. Finally, TSA reduced the expression of Bcl-2, an important survival protein in lung cancer cells, partly through upregulation of miR-15a/16-1. Therefore, this offers a therapeutic strategy that lung cancer patients who exhibit low level of miR-15a/16-1 or high activity of HDACs may benefit from HDACs inhibitor-based therapy.

Citing Articles

Recent advances on high-efficiency of microRNAs in different types of lung cancer: a comprehensive review.

Sadeghi M, Lotfi M, Soltani N, Farmani E, Fernandez J, Akhlaghitehrani S Cancer Cell Int. 2023; 23(1):284.

PMID: 37986065 PMC: 10661689. DOI: 10.1186/s12935-023-03133-z.

Deciphering the Mysterious Relationship between the Cross-Pathogenetic Mechanisms of Neurodegenerative and Oncological Diseases.

Aleksandrova Y, Neganova M Int J Mol Sci. 2023; 24(19).

PMID: 37834214 PMC: 10573395. DOI: 10.3390/ijms241914766.

Research progress in effects of microRNA15a and microRNA16 on fibrotic diseases.

Wen D, Wang J Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2023; 48(5):743-749.

PMID: 37539577 PMC: 10930399. DOI: 10.11817/j.issn.1672-7347.2023.220129.

An Update of Epigenetic Drugs for the Treatment of Cancers and Brain Diseases: A Comprehensive Review.

Sahafnejad Z, Ramazi S, Allahverdi A Genes (Basel). 2023; 14(4).

PMID: 37107631 PMC: 10137918. DOI: 10.3390/genes14040873.

Deleted in lymphocytic leukemia 2 (DLEU2): a possible biomarker that holds promise for future diagnosis and treatment of cancer.

Qu X, Cao Y, Xing Y, Liu Q, Li H, Yang W Clin Transl Oncol. 2023; 25(10):2772-2782.

PMID: 37095423 PMC: 10462543. DOI: 10.1007/s12094-023-03149-x.

References

Ziegler A, Luedke G, Fabbro D, Altmann K, Stahel R, Zangemeister-Wittke U . Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J Natl Cancer Inst. 1997; 89(14):1027-36. DOI: 10.1093/jnci/89.14.1027. View

Kaddar T, Chien W, Bertrand Y, Pages M, Rouault J, Salles G . Prognostic value of miR-16 expression in childhood acute lymphoblastic leukemia relationships to normal and malignant lymphocyte proliferation. Leuk Res. 2009; 33(9):1217-23. DOI: 10.1016/j.leukres.2008.12.015. View

Choi Y . Induction of apoptosis by trichostatin A, a histone deacetylase inhibitor, is associated with inhibition of cyclooxygenase-2 activity in human non-small cell lung cancer cells. Int J Oncol. 2005; 27(2):473-9. View

Tsai H, Baylin S . Cancer epigenetics: linking basic biology to clinical medicine. Cell Res. 2011; 21(3):502-17. PMC: 3193419. DOI: 10.1038/cr.2011.24. View

Bandi N, Vassella E . miR-34a and miR-15a/16 are co-regulated in non-small cell lung cancer and control cell cycle progression in a synergistic and Rb-dependent manner. Mol Cancer. 2011; 10:55. PMC: 3120797. DOI: 10.1186/1476-4598-10-55. View

Wistuba I, Gazdar A . Lung cancer preneoplasia. Annu Rev Pathol. 2007; 1:331-48. DOI: 10.1146/annurev.pathol.1.110304.100103. View

Cho W . MicroRNAs in cancer - from research to therapy. Biochim Biophys Acta. 2009; 1805(2):209-17. DOI: 10.1016/j.bbcan.2009.11.003. View

Brazelle W, Kreahling J, Gemmer J, Ma Y, Cress W, Haura E . Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells. PLoS One. 2010; 5(12):e14335. PMC: 3001870. DOI: 10.1371/journal.pone.0014335. View

Lerner M, Harada M, Loven J, Castro J, Davis Z, Oscier D . DLEU2, frequently deleted in malignancy, functions as a critical host gene of the cell cycle inhibitory microRNAs miR-15a and miR-16-1. Exp Cell Res. 2009; 315(17):2941-52. DOI: 10.1016/j.yexcr.2009.07.001. View

10.

Navarro A, Diaz T, Gallardo E, Vinolas N, Marrades R, Gel B . Prognostic implications of miR-16 expression levels in resected non-small-cell lung cancer. J Surg Oncol. 2011; 103(5):411-5. DOI: 10.1002/jso.21847. View

11.

Yoo C, Jones P . Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov. 2006; 5(1):37-50. DOI: 10.1038/nrd1930. View

12.

Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C . Cancer statistics, 2006. CA Cancer J Clin. 2006; 56(2):106-30. DOI: 10.3322/canjclin.56.2.106. View

13.

Negrini M, Ferracin M, Sabbioni S, Croce C . MicroRNAs in human cancer: from research to therapy. J Cell Sci. 2007; 120(Pt 11):1833-40. DOI: 10.1242/jcs.03450. View

14.

Bandi N, Zbinden S, Gugger M, Arnold M, Kocher V, Hasan L . miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res. 2009; 69(13):5553-9. DOI: 10.1158/0008-5472.CAN-08-4277. View

15.

Cimmino A, Calin G, Fabbri M, Iorio M, Ferracin M, Shimizu M . miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005; 102(39):13944-9. PMC: 1236577. DOI: 10.1073/pnas.0506654102. View

16.

Lim L, Lau N, Garrett-Engele P, Grimson A, Schelter J, Castle J . Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005; 433(7027):769-73. DOI: 10.1038/nature03315. View

17.

Diaz-Garcia C, Agudo-Lopez A, Perez C, Lopez-Martin J, Rodriguez-Peralto J, de Castro J . DICER1, DROSHA and miRNAs in patients with non-small cell lung cancer: implications for outcomes and histologic classification. Carcinogenesis. 2013; 34(5):1031-8. DOI: 10.1093/carcin/bgt022. View

18.

Cho W . Promises and challenges in developing miRNA as a molecular diagnostic tool for lung cancer. Expert Rev Mol Diagn. 2011; 11(8):763-6. DOI: 10.1586/erm.11.71. View

19.

Luszczek W, Cheriyath V, Mekhail T, Borden E . Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression. Mol Cancer Ther. 2010; 9(8):2309-21. DOI: 10.1158/1535-7163.MCT-10-0309. View

20.

Cho W . Targeting signaling pathways in lung cancer therapy. Expert Opin Ther Targets. 2012; 17(2):107-11. DOI: 10.1517/14728222.2013.729043. View